Bingham Private Wealth’s Verona Pharma VRNA Stock Holding History

Bingham Private Wealth’s Portfolio VRNA Stock Details VRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	$240K	Buy	+2,536	New	+$188K	0.23%	133

Other funds holding VRNA

Janus Henderson Group

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Summit Partners Public Asset Management Boston, Massachusetts $3.72B AUM 162.29% 1-Year Est. Return

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Bingham Private Wealth's VRNA Position: Q2 2025 in Review

Bingham Private Wealth opened a new position in Verona Pharma (VRNA) in Q2 2025: 2,536 shares worth $240K. The stake represents 0.23% of the portfolio and ranks #133 among its holdings.

292 funds tracked by Wall St. Rank hold VRNA as of Q2 2025.

Bingham Private Wealth held 2,536 shares of Verona Pharma worth $240K as of Q2 2025.
Verona Pharma was a new Bingham Private Wealth position in Q2 2025.
Verona Pharma made up 0.23% of Bingham Private Wealth's portfolio in Q2 2025, its #133 holding.
292 funds tracked by Wall St. Rank held Verona Pharma as of Q2 2025.

Based on Bingham Private Wealth's 13F filing for Q2 2025, filed 23 Jul 2025.